Trial Profile
A Exploratory Phase 2,Placebo-controlled,Randomized,Double-blind,Multicenter,Parallel-group Study to Evaluate Efficacy and Safety of TMX-049 in Hyperuricemic Patients with or without Gout
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs TMX 049 (Primary) ; Febuxostat
- Indications Gout; Hyperuricaemia
- Focus Therapeutic Use
- Sponsors Teijin Pharma
- 06 Jun 2018 Status changed from recruiting to completed.
- 01 Jun 2017 New trial record